Food and Drug Administration (FDA)
NEWS
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.
What’s the best way to address high drug prices? That’s a tough question, but one angle that gets less public attention is the high cost of early-stage development.
The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.
JOBS
IN THE PRESS